Key Points
- CFO Steven Cook sold 1,884 shares on March 13 at an average price of $13.94 for a total of $26,262.96, leaving him with 200,512 shares (a 0.93% decrease); the sale was disclosed in an SEC filing.
- Omada beat expectations for the quarter with $0.08 EPS vs. a -$0.04 consensus and $75.85 million in revenue; shares opened at $14.62 (down 1.2%), with a market cap of about $861 million and a 52-week range of $10.28–$28.40.
- Analysts hold a consensus of "Moderate Buy" with an average target price of $23.60, though price targets have been mixed (JPMorgan cut to $26, BMO to $18) and ratings include eight Buys, two Holds and one Sell.
Omada Health, Inc. (NASDAQ:OMDA - Get Free Report) CFO Steven Cook sold 1,884 shares of the firm's stock in a transaction on Friday, March 13th. The stock was sold at an average price of $13.94, for a total transaction of $26,262.96. Following the transaction, the chief financial officer directly owned 200,512 shares of the company's stock, valued at approximately $2,795,137.28. This represents a 0.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Omada Health Stock Down 1.2%
Shares of NASDAQ OMDA opened at $14.62 on Wednesday. Omada Health, Inc. has a 52-week low of $10.28 and a 52-week high of $28.40. The stock has a market capitalization of $861.41 million and a P/E ratio of -86.00. The stock's 50 day moving average price is $13.85 and its two-hundred day moving average price is $18.26.
Omada Health (NASDAQ:OMDA - Get Free Report) last posted its quarterly earnings results on Thursday, March 5th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.12. The firm had revenue of $75.85 million for the quarter.
Wall Street Analysts Forecast Growth
OMDA has been the subject of several recent research reports. JPMorgan Chase & Co. lowered their price target on shares of Omada Health from $32.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, March 12th. The Goldman Sachs Group reiterated a "buy" rating and set a $26.00 price target on shares of Omada Health in a research report on Friday, January 16th. Needham & Company LLC reiterated a "buy" rating and issued a $28.00 target price on shares of Omada Health in a report on Thursday, January 22nd. Wall Street Zen raised Omada Health from a "hold" rating to a "buy" rating in a report on Saturday. Finally, BMO Capital Markets reduced their price target on shares of Omada Health from $27.00 to $18.00 and set an "outperform" rating for the company in a research report on Friday, March 6th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $23.60.
Check Out Our Latest Stock Report on OMDA
Institutional Investors Weigh In On Omada Health
Hedge funds have recently bought and sold shares of the company. Strs Ohio acquired a new stake in Omada Health in the 3rd quarter valued at approximately $38,000. Raymond James Financial Inc. bought a new position in shares of Omada Health during the 2nd quarter worth about $32,000. Bellevue Group AG boosted its holdings in Omada Health by 0.7% during the third quarter. Bellevue Group AG now owns 251,791 shares of the company's stock valued at $5,567,000 after purchasing an additional 1,791 shares in the last quarter. Quarry LP bought a new stake in Omada Health in the fourth quarter valued at $29,000. Finally, Barclays PLC grew its holdings in shares of Omada Health by 14.6% in the 4th quarter. Barclays PLC now owns 14,850 shares of the company's stock worth $234,000 after purchasing an additional 1,888 shares during the last quarter.
About Omada Health
(
Get Free Report)
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company's platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
